Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | CCR8 | P51685 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.33 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26880654 | 0.81 | CCR1 (0.42) | CCR1CCR5CCR8HTTHSD17B10 | |
| SCHEMBL30390711 | 0.81 | CCR1 (0.42) | CCR1CCR5CCR8HTTHSD17B10 | |
| SCHEMBL29954308 | 0.79 | CCR1 (0.41) | CCR1CCR5CCR8HTTHSD17B10 | |
| SCHEMBL28052033 | 0.79 | CCR1 (0.41) | CCR1CCR5CCR8HTTHSD17B10 | |
| SCHEMBL12479704 | 0.77 | HTT (0.33) | HTTHSD17B10LMNASMN1; SMN2 | |
| SCHEMBL12479706 | 0.77 | HTT (0.33) | HTTHSD17B10LMNASMN1; SMN2 | |
| SCHEMBL28114355 | 0.75 | CCR1 (0.48) | CCR1CCR5CCR8TRIM24TRIM33 | |
| SCHEMBL29955416 | 0.75 | CCR1 (0.48) | CCR1CCR5CCR8TRIM24TRIM33 | |
| SCHEMBL2514186 | 0.74 | TRIM24 (0.52) | CCR1CCR5CCR8HTTHSD17B10 | |
| SCHEMBL30524918 | 0.74 | TRIM24 (0.52) | CCR1CCR5CCR8HTTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110003200-A | P2X7 regulator | 詹森药业有限公司 | 2019-07-12 | — | — | CN | claimed |
| CN-105209464-B | P2X7 modulators | 詹森药业有限公司 | 2019-01-01 | — | — | CN | claimed |
| EP-2970267-B3 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-30 | — | — | EP | claimed |
| CN-110003200-B | P2X7 modulators | 詹森药业有限公司 | 2021-11-26 | — | — | CN | disclosed |
| EP-3746429-A1 | PROCESSES FOR PREPARING (1 -(3-FLUORO-2-(TRIFLUOROMETHYL)ISONICOTINYL)PIPERIDINE-4-ONE) | Incyte Corporation (US) | 2020-12-09 | — | — | EP | disclosed |
| WO-2019152374-A1 | PROCESSES FOR PREPARING (1 -(3-FLUORO-2-(TRIFLUOROMETHYL)ISONICOTINYL)PIPERIDINE-4-ONE) | INCYTE CORPORATION (US) | 2019-08-08 | — | — | WO | disclosed |
| CN-110003200-A | P2X7 regulator | 詹森药业有限公司 | 2019-07-12 | — | — | CN | disclosed |
| EP-3495365-A1 | P2X7 MODULATORS | Janssen Pharmaceutica NV (BE) | 2019-06-12 | — | — | EP | disclosed |
| CN-105209464-B | P2X7 modulators | 詹森药业有限公司 | 2019-01-01 | — | — | CN | disclosed |
| EP-3239151-B1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-07 | — | — | EP | disclosed |
| EP-3239151-A1 | P2X7 MODULATORS | Janssen Pharmaceutica NV (BE) | 2017-11-01 | — | — | EP | disclosed |
| US-9085555-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2015-07-21 | — | — | US | disclosed |
| US-9085555-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2015-07-21 | — | — | US | disclosed |
| WO-2014152604-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-25 | — | — | WO | disclosed |
| CN-103402996-A | Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (AMD) | NOVARTIS AG | 2013-11-20 | — | — | CN | disclosed |
| EP-2661433-A1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | Novartis AG (CH) | 2013-11-13 | — | — | EP | disclosed |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2012-11-22 | — | — | US | disclosed |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2012-11-22 | — | — | US | disclosed |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2012-11-22 | — | — | US | disclosed |
| WO-2012093101-A1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | NOVARTIS AG (CH) | 2012-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295884-A1 | Complement pathway modulators and uses thereof | C5, C3AR1, C9 | CCR1 658/4885CCR5 470/4885CCR8 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.